drugset / Trial / NCT05574387

Metformin as Added on Therapy in Patients With Ulcerative Colitis

NCT05574387 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization

Timeline

Start
2023-01-20
Primary completion
2026-12
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 500 mg —